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Lymphomatoid granulomatosis (LG) is a potentially malignant lymphoproliferative disorder. The lung is the most 
common involved site, followed by the skin and nervous system. However, LG of the central nervous system 
presenting with Parkinsonism is very rare. We report a patient with LG who presented with parkinsonian features 
such as bilateral rigidity, bradykinesia, and agitation. Brain magnetic resonance imaging showed multifocal punctuate 
enhanced lesions in both supra- and infratentorial areas. Steroid pulse therapy resulted in a dramatical improve-
ment in the symptoms and MRI abnormalities.
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Lymphomatoid granulomatosis (LG) is an atypical, 
potentially malignant lymphoproliferative disorder that 
mainly involves the lung, followed by the skin and the 
brain.
1 The central nervous system (CNS) is involved in 
up to one-third of LG patients. However, isolated CNS 
involvement is rare,
2,3  and its clinical features are variable. 
We report a patient who presented with subacute onset 
of symmetric Parkinsonism associated with LG involving 
the CNS.
CASE REPORT
A 21-year-old man was admitted for the evaluation of 
leukopenia and thrombocytopenia. He was diagnosed with 
lymphoblastic lymphoma and treated with a chemothera-
peutic regimen (Hyper-CVAD). Ten days after the chemo-
therapy, he became agitated and exhibited temporary 
whole-body tremor that made him unable to stand still. 
On examination, he appeared dull and apathetic, and his 
gait was slow and characterized by short steps, shuffling, 
the paucity of arm swing, and difficulty in turning of the 
body. His posture was stooped forward, and he com-
plained of a sense of heaviness and clumsiness in his 
activities of daily living. His family noticed that he took 
a long time to respond to questions. There were bilateral 
mild-to-moderate postural and action tremors, symmetric 
and moderate rigidity with bradykinesia, and moderately 
shuffling gait in a stooped posture according to the Uni-
fied Parkinson’s Disease Rating Scale (UPDRS).
4 Labora-
tory findings were inconclusive. Cerebrospinal fluid (CSF) 
findings were as followed: pleocytosis (90 WBCs/mm
3, 
70% mononuclear cells), no red blood cells, mild ele-
vation of protein (51.9 mg/dL), and normal glucose (72 Lee AY, et al. Lymphomatoid Granulomatosis Presenting with Parkinsonism
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Figure 1. Brain MRI performed before treatment with steroid. 
T2-weighted MRI showed disseminated and multifocal hyper-
intense lesions in both basal ganglia, thalamus, cerebral cortex, 
and white matter (A, B), and disseminated multiple punctuate 
enhanced lesions in the corresponding areas of the T1- 
weighted images with gadolinium enhancement (C, D).
mg/dL). Neither microorganisms nor malignant lympho-
cytes were detected in the CSF. PCR of CSF samples 
for mycobacterium tuberculosis and an antibody against 
fungus produced negative results. 
Radiologic searches for systemic lesions related with 
LG showed no abnormalities. T2-weighted axial MRI 
showed numerous disseminated hyperintense lesions in 
the whole brain, mainly in both basal ganglia, thalamus, 
cerebral cortex, white matter, brainstem, and cerebellum. 
The lesions showed multifocal punctuated enhancement 
with gadolinium (Fig. 1). We used a steroid to treat LG 
because the patient and his family did not allow us to 
perform a brain biopsy. Pulse therapy with methyl-
prednisolone (1000 mg/day) for 5 days resulted in most 
of the disseminated lesions disappearing in follow-up 
brain MRI, and they had completely resolved 2 months 
later (Fig. 2).
Whilst mild shuffling of the gait remained (mild se-
verity according to the UPDRS
4), the parkinsonian 
features in the limbs of the patient such as tremor, 
rigidity, and bradykinesia were no longer present after 
the therapy. His facial expression was appropriate and 
his speed of thought processing was improved. Cognitive 
evaluation using the Korean version of Wechsler Adult 
Intelligence Scale (KWAIS) had initially showed a lower- 
than-average IQ and dissociation between verbal and 
performance IQ. Two months later, he showed better 
cognitive function and an average IQ on the KWAIS.
DISCUSSION
We experienced a patient who presented only with 
subacute-onset symmetric Parkinsonism associated with 
disseminated multifocal enhanced lesions in the brain. 
He had been previously diagnosed with lymphoblastic 
lymphoma and treated with Hyper-CVAD. Multiple 
disseminated lesions in the subcortical gray matter, 
including the basal ganglia and thalamus, might have 
been responsible for the Parkinsonism and slowing of 
thought processing in this patient. 
CNS complications of hematologic neoplasm are caused 
either by the primary disease or by the effects of therapy.
5 
LG is one of the rare diseases that causes CNS com-
plications in patients with hematologic neoplasm. Multi-
focal gadolinium-enhanced lesions in the brain can be 
caused by infiltration of primary hematologic disease or 
opportunistic infection with disseminated tuberculosis or Journal of Clinical Neurology: Vol. 3, No. 2, 2007
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Figure 2. Brain MRI performed 2 months after treatment 
with steroid. Multiple punctuate disseminated lesions were 
completely resolved in T2-weighted (A, B) and gadolinium- 
enhanced T1-weighted (C, D) MRI images.
fungus, so clinicians should differentiate LG and infec-
tious causes. Neither malignant cells nor microorganisms 
in the CSF were found or grown in the present case. 
Also, pulse therapy with a steroid was effective for the 
parkinsonian symptoms and the brain lesions without the 
use of antituberculous and antifungal agents. The known 
CNS complications of Hyper-CVAD are only related to 
steroids,
6 and hence the present subject represents a 
novel case. MRI is more sensitive than CSF cytologic 
analysis or flow cytometry for detecting CNS involve-
ment from LG.
7 Therefore, we considered the CNS 
lesion in this case to be LG since there was no evidence 
of opportunistic infections or complications of chemo-
therapy, and the patient showed specific MRI findings of 
LG and a good response to steroid therapy. Despite 
these findings, we were unable to make a definitive 
diagnosis due to the lack of pathologic data.
LG presents diverse neuroimaging features, such as 
multiple punctuate or linear enhancements, ring-like 
enhancements, large enhanced mass lesions, leptome-
ningeal involvement, and choroid plexus involvement.
7,8 
Disseminated multifocal enhancement in the present case 
is a typical pattern of angiocentric involvement with LG. 
The clinical features of its CNS involvement also are 
variable, including headache, seizure, blindness, cranial 
nerve palsies, hemiparesis, ataxia, spastic gait, dementia, 
and altered consciousness.
2,3 Parkinsonism is a rare pre-
senting symptom of LG.
9 
Parkinsonism could be the only presenting manifes-
tation of CNS involvement of LG, and it is worth 
applying steroid therapy in cases with clinical suspicion 
because the prognosis of LG involved CNS is variable, 
ranging from spontaneous resolution to rapid fatality.
10
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